Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes
| Autor: | Mitsuyoshi Namba, Yoshiki Kusunoki, Tomoyuki Katsuno, Masayuki Miuchi, Kazuki Murai, Kana Miyakoshi, Masaru Tokuda, Fumihiro Ochi, Tomoya Hamaguchi, Jun-ichiro Miyagawa |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male medicine.medical_specialty Injections Subcutaneous Endocrinology Diabetes and Metabolism Blood lipids Incretin Type 2 diabetes Body Mass Index Endocrinology Gastrointestinal Agents Japan Glucagon-Like Peptide 1 Weight loss Internal medicine Diabetes mellitus Weight Loss medicine Humans Hypoglycemic Agents Obesity Antihypertensive Agents Aged Glycemic Venoms business.industry Anticholesteremic Agents Nausea Middle Aged medicine.disease Blood pressure Diabetes Mellitus Type 2 Hyperglycemia Exenatide Female Anti-Obesity Agents medicine.symptom Peptides business Follow-Up Studies medicine.drug |
| Zdroj: | Endocrine Journal. 61:365-372 |
| ISSN: | 1348-4540 0918-8959 |
| DOI: | 10.1507/endocrj.ej14-0009 |
| Popis: | The effects of exenatide on glycemic control, lipid metabolism, blood pressure, and gastrointestinal symptoms were investigated in obese Japanese patients with type 2 diabetes mellitus. Twenty-six outpatients were enrolled and administered 5 μg of exenatide twice daily. If there was insufficient weight loss and/or insufficient improvement in glycemic control, the dose was increased to 10 μg twice daily. Follow-up was continued until the 12th week of administration. Hemoglobin A1c, glycoalbumin, fasting plasma glucose, body weight, fasting serum C-peptide, serum lipids, blood pressure, and pulse rate were measured before and after the observation period. In the initial phase of exenatide therapy, each patient received a diary to record gastrointestinal symptoms. During treatment with exenatide, hemoglobin A1c decreased significantly and serum C-peptide increased significantly. Body weight, low-density lipoprotein cholesterol, and systolic blood pressure decreased significantly. Nausea was the most frequent gastrointestinal symptom and occurred in 16 patients. Its onset was noted at a mean of 1.7 h after injection, the mean duration was 1.1 h, and it continued for a mean of 9.3 days after the initiation of administration. Patients with nausea showed a significant decrease in hemoglobin Alc, glycoalbumin, or body weight compared with those without nausea. These findings suggest that a more marked improvement in metabolic parameters by exenatide can be partly dependent on the manifestation of gastrointestinal symptoms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|